Who Paid My Doc
Jill Nohl
Thoracic Surgery (Cardiothoracic Vascular Surgery) Omaha, NE Nurse Practitioner
NPI 1487175261 CMS profile 3080919
Emile 42Nd St, Omaha, NE 68198
General payments
$8,564
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Jill Nohl of Omaha, NE is reported in the CMS Open Payments database as having received $8,564 across 110 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 63rd percentile of Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
6 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $1,143 | 26 | |
| 2024 | General | $3,079 | 42 | |
| 2023 | General | $4,143 | 35 | |
| 2022 | General | $135 | 4 | |
| 2021 | General | $56 | 1 | |
| 2020 | General | $8 | 2 |
Beside peers
- Jill Nohl
- Thoracic Surgery (Cardiothoracic Vascular Surgery) median
- Middle half of Thoracic Surgery (Cardiothoracic Vascular Surgery)
- National median
In program year 2025, general payments to Jill Nohl were reported at $1,143. Among 4,073 Thoracic Surgery (Cardiothoracic Vascular Surgery) profiles paid that year, the median was $791 and the middle half received between $208 and $3,074.
Show as a table
| Year | Jill Nohl | Thoracic Surgery (Cardiothoracic Vascular Surgery) median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | $886 | $178–$3,167 | $163 |
| 2020 | $8 | $341 | $108–$1,605 | $114 |
| 2021 | $56 | $453 | $125–$1,886 | $132 |
| 2022 | $135 | $695 | $180–$2,566 | $149 |
| 2023 | $4,143 | $745 | $205–$2,662 | $160 |
| 2024 | $3,079 | $799 | $214–$2,967 | $164 |
| 2025 | $1,143 | $791 | $208–$3,074 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 20 drugsPart D claims
839
Drug cost
$93,800
Branded share of claims
12.2%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Jardiance Empagliflozin | Brand | 58 | $42,661 | |
| Entresto Sacubitril/Valsartan | Brand | 44 | $40,068 | |
| Doxycycline Hyclate | Generic | 12 | $2,420 | |
| Potassium Chloride | Generic | 51 | $2,246 | |
| Enoxaparin Sodium | Generic | 17 | $1,712 | |
| Warfarin Sodium | Generic | 249 | $1,640 | |
| Torsemide | Generic | 36 | $647 | |
| Metoprolol Succinate | Generic | 49 | $553 | |
| Atorvastatin Calcium | Generic | 45 | $453 | |
| Pantoprazole Sodium | Generic | 48 | $316 |
The 10 drugs with the highest cost, of 20 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Billing to Medicare
Part B · data year 2024 · 7 billing codesPaid by Medicare
$6,439
Medicare patients
28
Services billed
121
| Condition among their Medicare patients | Relative to the most common | Share of patients |
|---|---|---|
| High blood pressure | 75% | |
| Heart failure | 75% | |
| Ischemic heart disease | 75% | |
| Atrial fibrillation | 75% | |
| Chronic kidney disease | 57% | |
| Diabetes | 54% | |
| Depression | 43% | |
| Osteoporosis | 0% |
Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.
Records
110 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Thoracic Surgery (Cardiothoracic Vascular Surgery) in Nebraska
Helenmari Merritt
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Omaha, NE
Richard Thompson
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Lincoln, NE
John Batter
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Omaha, NE
Ryan Shelstad
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Lincoln, NE
Kim Duncan
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Omaha, NE
David Berkheim
Thoracic Surgery (Cardiothoracic Vascular Surgery) · Omaha, NE
Related records
Thoracic Surgery (Cardiothoracic Vascular Surgery) in Nebraska
Practitioners in the same specialty and state, ranked by reported value.
All Thoracic Surgery (Cardiothoracic Vascular Surgery)
Everyone recorded under this specialty, nationwide.
Doctors in Nebraska
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.